HC Wainwright Lowers Neumora Therapeutics (NASDAQ:NMRA) Price Target to $18.00

Neumora Therapeutics (NASDAQ:NMRA) had its target price reduced by stock analysts at HC Wainwright from $30.00 to $18.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other equities analysts also recently weighed in on NMRA. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday. Bank of America dropped their price target on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Finally, Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $29.00 to $4.00 in a research report on Thursday, January 2nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Neumora Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $11.50.

Neumora Therapeutics Trading Up 1.4 %

Neumora Therapeutics stock opened at $1.43 on Tuesday. The stock has a 50-day moving average price of $2.83 and a 200 day moving average price of $8.76. Neumora Therapeutics has a 52 week low of $1.35 and a 52 week high of $21.00. The stock has a market cap of $231.03 million, a PE ratio of -0.76 and a beta of 2.50.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. On average, equities analysts predict that Neumora Therapeutics will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Neumora Therapeutics in the fourth quarter worth approximately $61,000. PNC Financial Services Group Inc. purchased a new position in shares of Neumora Therapeutics during the 4th quarter valued at $64,000. Quantbot Technologies LP acquired a new position in shares of Neumora Therapeutics in the fourth quarter worth $92,000. PEAK6 LLC purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth about $117,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Neumora Therapeutics during the 4th quarter worth $135,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.